Natera Inc Stock
€269.60
Your prediction
Financial data and news for Natera
sharewise wants to provide you with the best news and tools for Natera, so we directly link to the best financial data sources.
Financials
News
Natera Q2 Earnings Call Highlights
Natera (NASDAQ:NTRA) reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and
Allogene Therapeutics Q1 Earnings Call Highlights
Allogene Therapeutics (NASDAQ:ALLO) said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a
Natera Q1 Earnings Call Highlights
Natera (NASDAQ:NTRA) reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a
What to Know About This Natera Insider Transaction as Shares Surge to Record Highs
Solomon Moshkevich, president of clinical diagnostics at Natera, Inc. (NASDAQ:NTRA), sold 3,410 shares of common stock on August 3, according to an SEC Form 4 filing.
Transaction value based on SEC
A Natera Co-Founder Sold 2,000 Shares From a Spouse's Account. Here's What It Suggests
Executive Chairman Matthew Rabinowitz reported a sale of 2,000 shares of Natera, Inc. (NASDAQ:NTRA) in a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price
Should You Worry That a Natera Co-Founder Sold Shares? Here's What Long-Term Investors Should Know
Matthew Rabinowitz, the executive chairman of Natera, Inc. (NASDAQ:NTRA), sold 731 shares of common stock at $267.99 per share on August 3, according to an SEC Form 4 filing.
Transaction value based
A Natera Insider's Shares Vested Before the Firm Reported Revenue Surged 38%. Here's How to Read It
Michael Burkes Brophy, the chief financial officer of Natera, Inc. (NASDAQ:NTRA), sold 795 shares of common stock at $271.74 per share in transactions executed on August 3 and August 4, according to
A Natera Co-Founder Sold Into Record Highs. Here's What Long-Term Investors Should Know
Jonathan Sheena, a co-founder of Natera, Inc. (NASDAQ:NTRA), sold 9,150 shares of common stock at $315.66 per share on August 7, according to an SEC Form 4 filing.
Transaction value based on SEC
Stanley Druckenmiller Put 18% of His $3.4 Billion Portfolio in This One Stock. Is Natera a Buy?
It can pay to track what the big investors on Wall Street are trading in quarterly 13-F filings. This quarter, legendary hedge fund manager Stanley Druckenmiller added to his largest stock position
Billionaire Stanley Druckenmiller's Top Holding Isn't Nvidia. Instead, It's This Under-the-Radar Stock That Wall Street Loves.
He's a retired hedge fund manager, but people still want to know what billionaire Stanley Druckenmiller is doing with his money. The answer? Investing in the medical diagnostic company Natera
Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)
Your personal portfolio doesn't necessarily need to mirror a billionaire investor's holdings. But let's face it -- they manage billion-dollar portfolios for a reason.
And that's what makes Stanley